-
Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit
Monday, May 16, 2011 - 2:11pm | 399Eli Lilly and Company (NYSE: LLY) has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s (NASDAQ: AMLN) lawsuit filed in the United States District Court for the Southern District of California. The lawsuit alleges that Lilly is not using commercially reasonable efforts...
-
Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150
Monday, May 16, 2011 - 11:28am | 88Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Ranitidine 150, a generic version of Zantac 150®. Zantac 150 is indicated for the relief of heartburn...
-
Lilly Says Suit Is Without Merit, Will Vigorously Defend Position
Monday, May 16, 2011 - 10:21am | 268Eli Lilly and Company (NYSE: LLY) has provided the following statement in response to a lawsuit and motion for temporary restraining order filed by Amylin Pharmaceuticals, Inc. against Lilly. The action was filed in the United States District Court for the Southern District of California. "We...
-
Lilly Provides Statement in Response to Amylin Lawsuit
Monday, May 16, 2011 - 9:54am | 197Eli Lilly and Company (NYSE: LLY) has provided the following statement in response to a lawsuit and motion for temporary restraining order filed by Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) against Lilly. The action was filed in the United States District Court for the Southern District of...
-
Teva Says Taiyo Purchase Puts It Near Market Leader, Will Consider More Acquisitions
Monday, May 16, 2011 - 9:53am | 41Teva (NASDAQ: TEVA) says, "the purchase of Taiyo puts it near market leader... Taiyo deal puts Teva near Japan market leader... Japan's generic penetration could reach 60%, currently at 23%... Teva will consider more acquisitions."
-
Watson Launches Generic AMRIX
Monday, May 16, 2011 - 9:23am | 67Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical...
-
Stocks to watch on 5/16/11- VITA, LOW, NDAQ, ICE, NYX, PRM, JCP, JOYG, IRM, TCG, DISH, RDC, NFLX, SYK…
Monday, May 16, 2011 - 9:15am | 1372Orthovita Inc. (VITA) agreed to be acquired by Stryker Corp. (SYK) for a $3.85 a share in cash in a deal valued at $316 million. Lowe's Cos. (LOW) estimated that for the fiscal second quarter ending July 29, it would earn 65 cents to 69 cents a share on 4% higher total sales and 2% higher same-...
-
Deutsche Bank Comments on Victrelis FDA Approval
Monday, May 16, 2011 - 8:16am | 91FDA approval came on May 13 and Merck & Co. Inc. (NYSE: MRK) will launch Victrelis this month, Deutsche Bank reports. “Labeling was generally very favorable for boceprevir, with no major exclusions or restrictions (other than for DDIs), and potential RGT options for most patients -- in our...
-
Codexis Announces Expansion of Collaboration with Teva Pharmaceutical
Monday, May 16, 2011 - 8:06am | 130Codexis, Inc. (Nasdaq: CDXS) today announced the continued expansion of its collaboration with Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA). Codexis has now successfully completed technology transfer of custom biocatalysts for manufacture of three undisclosed pharmaceutical products to Teva...
-
Long-Term Study Demonstrates Safety and Efficacy of SYMBICORT® in African American Patients with Asthma
Monday, May 16, 2011 - 8:02am | 117AstraZeneca (NYSE: AZN) today announced results from a long-term study comparing SYMBICORT® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe...
-
Citi Comments On Pfizer In A 1Q11 10-Q Review (PFE)
Monday, May 16, 2011 - 7:46am | 106In a recent report, Citi has reiterated a $23.00 price target on Pfizer (NYSE: PFE) and maintained a Hold rating on the company in a 1Q11 10-Q Review. Citi has also noted that there needs to be business development in the primary care segment to quell decreasing profitability. In the report, Citi...
-
Bank Of America Raising PT On LLY To $43
Monday, May 16, 2011 - 7:43am | 159Following beat Q1 results from the major US pharma stocks, Bank of America is raising its price target to $43 and reiterating its Buy rating on Eli Lilly & Co. (NYSE: LLY). According to Bank of America, “With each of the 4 US Major Pharma stocks beating Q1 results and investors beginning to...
-
Jefferies Raises PT From $21.00 To $25.00 On Amarin (AMRN)
Monday, May 16, 2011 - 7:39am | 64In a recent report, Jefferies has raised the price target on Amarin (NASDAQ: AMRN) from $21.00 to $25.00 after a AMR101 patent discussion with the FDA. In the report, Jefferies said, "We believe a longer-than-expected Hatch-Waxman patent extension of 5 years (vs. company guidance of 2 years)...
-
Citi Reviews Allergan 1Q11
Monday, May 16, 2011 - 7:35am | 128Allergan Inc. (NYSE: AGN) increased its workforce by 300 to 9,500 in 1Q11 after a +900 increase in 2010, Citi reports. “We assume most of the increase came from ex-US markets where AGN is expanding its operations in both eye care & aesthetics,” Citi writes. “On its 1Q11 call AGN indicated that...
-
Bank Of America Raises PT To $29 On MRK
Monday, May 16, 2011 - 7:31am | 145Bank of America is raising its price target to $41 and is reiterating its Buy rating on Merck & Co. (NYSE: MRK), as investors begin to warm up to pharma stocks again. Says Bank of America, in the report, “With each of the 4 US Major Pharma stocks beating Q1 results and investors beginning to...